ARCHIVES

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Biomedical Panel Report Will Support Cancer Program, Targeted Research

January 16, 1976

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds

April 29, 2011

Funding opportunities listed.

March 12, 2004

Recommendation By Patients; report Of Protocol Committee

August 9, 1996

In Brief: Holleb Named Memorial Distinguished Alumnus; Hankey Appointed DCPC Statistics Branch Chief

September 1, 1989